GLP-1, SGLT2 medications may lower stroke survivor’s risk of …
2 days ago · The SGLT2 medications canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are approved by the FDA for the treatment of Type 2 diabetes. To analyze the impact of these two classes of medications, this study reviewed medical records for more than 7,000 adults who had clot-caused, or ischemic , strokes between January 2000 and June 2022.
GLP-1 and SGLT2 Drugs May Help Prevent Second Strokes and …
1 day ago · In a preliminary study set to be presented at the American Heart Association’s Scientific Sessions 2024, a team of researchers from the Mayo Clinic in Rochester, Minnesota, found that GLP-1 receptor agonists and SGLT2 inhibitors may significantly reduce the risk of heart attacks, second strokes, and death in adults who have previously had an ischemic stroke.
GLP-1 and SGLT2 inhibitors show promise in ... - News-Medical.net
2 days ago · After an average follow-up of three years, the analysis found: Adults who were taking either a GLP-1 or an SGLT2 had a 74% lower risk of death and an 84% lower risk of having a heart attack ...
GLP-1, SGLT2 medications may lower stroke sur | EurekAlert!
2 days ago · Adults who were taking either a GLP-1 or an SGLT2 had a 74% lower risk of death and an 84% lower risk of having a heart attack. Adults who were taking an SGLT2 were also at a 67% lower risk of ...
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults …
Oct 1, 2024 · Current practice Few therapies slow kidney disease progression and improve long term prognosis for adults living with CKD. SGLT-2 inhibitors have demonstrated cardiovascular and kidney benefits in adults with CKD with and without type 2 diabetes.
FDA Update: Sotagliflozin Approved For Broad HF Treatment
Jun 5, 2023 · The U.S. Food and Drug Administration (FDA) on May 26 approved a new drug application submitted by Lexicon Pharmaceuticals, Inc. for sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2 inhibitor for the treatment of heart failure (HF), including HF with preserved ejection fraction and HF with reduced ejection fraction.
FDA approves first SGLT1/SGLT2 inhibitor for heart failure
Jun 29, 2023 · Patients now have an even better chance at survival with the recent FDA approval of Inpefa, the brand name of the drug sotagliflozin. It is the first sodium glucose cotransporter (SGLT) inhibitor that addresses glucose reabsorption in both the kidneys and the small intestine.
SGLT2 inhibitors: A game-changer in preventing heart failure and …
Apr 9, 2024 · In a trial-level meta-analysis published in the journal Circulation, researchers assessed the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors (SGLT2i) on major adverse...
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse ...
Apr 7, 2024 · Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear.
SGLT2 inhibitors as the bedrock of therapy for heart failure
Sep 3, 2022 · Despite the differences in patient populations and study designs, the evidence is strikingly consistent and resoundingly clear—SGLT2 inhibitors are the bedrock of therapy for heart failure regardless of ejection fraction or care setting.
- Some results have been removed